Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning.

Journal: Nature biomedical engineering
Published Date: Sep 17, 2018

Abstract

The risk stratification of prostate cancer and breast cancer tumours from patients relies on histopathology, selective genomic testing, or on other methods employing fixed formalin tissue samples. However, static biomarker measurements from bulk fixed-tissue samples provide limited accuracy and actionability. Here, we report the development of a live-primary-cell phenotypic-biomarker assay with single-cell resolution, and its validation with prostate cancer and breast cancer tissue samples for the prediction of post-surgical adverse pathology. The assay includes a collagen-I/fibronectin extracellular-matrix formulation, dynamic live-cell biomarkers, a microfluidic device, machine-vision analysis and machine-learning algorithms, and generates predictive scores of adverse pathology at the time of surgery. Predictive scores for the risk stratification of 59 prostate cancer patients and 47 breast cancer patients, with values for area under the curve in receiver-operating-characteristic curves surpassing 80%, support the validation of the assay and its potential clinical applicability for the risk stratification of cancer patients.

Authors

  • Michael S Manak
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Jonathan S Varsanik
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Brad J Hogan
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Matt J Whitfield
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Wendell R Su
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Nikhil Joshi
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Nicolai Steinke
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Andrew Min
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Delaney Berger
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Robert J Saphirstein
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Gauri Dixit
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Thiagarajan Meyyappan
    Cellanyx Diagnostics, Beverly, MA, USA.
  • Hui-May Chu
    Anoixis Corporation , Natick, MA, USA.
  • Kevin B Knopf
    Cancer Commons, Los Altos, CA, USA.
  • David M Albala
    Associated Medical Professionals of New York, New York, NY, USA.
  • Grannum R Sant
    Department of Urology, Tufts University School of Medicine, Boston, MA, USA.
  • Ashok C Chander
    Cellanyx Diagnostics, Beverly, MA, USA. ashok@cellanyx.com.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals